
Dual-compound metabolic precision.
Retatrutide 25mg + Tirzepatide 30mg (55mg total) — combined triple- and dual-agonist cartridge.
RT Max 55mg is a combination cartridge pairing Retatrutide (25mg) with Tirzepatide (30mg) for layered GLP-1, GIP, and Glucagon receptor activation.
Combining Retatrutide's triple-receptor agonism with Tirzepatide's dual GLP-1 / GIP activation amplifies satiety signaling, slows gastric emptying, and compounds metabolic recomposition effects.
Week 1–2: 10 clicks weekly to assess tolerance. Titrate upward as tolerated under medical supervision.
Weekly subcutaneous injection via the pen. Rotate between abdomen, thigh, and upper arm.
Refrigerate at 2–8 °C. Do not freeze.
Most users report measurable changes within 2–4 weeks of consistent use. Full results typically emerge across an 8–12 week protocol.
Yes. Our compounds are designed to be modular. Pair with complementary stacks from Recovery, Longevity, or Metabolic collections — our specialists can recommend a structure.
Every batch ships with a Certificate of Analysis verifying purity above 99% from an independent ISO-accredited lab.
Unopened, temperature-intact vials may be returned within 14 days. Opened compounds are non-returnable for safety reasons.
MetabolicSLU-PP-332 AMPK activator that mimics the metabolic signature of endurance training.
MetabolicRetatrutide 50mg/3mL — triple agonist of GLP-1, GIP, and Glucagon receptors.
MetabolicTirzepatide 60mg/3mL — GLP-1 / GIP dual agonist for advanced fat loss.
MetabolicPre-filled 60mg/3ml MOTS-c pen — mitochondrially encoded peptide that boosts metabolic flexibility.